#### **COUNCIL MEETING** Sharing Our Passion For Life

## Palliative Care: Science, perceptions and the patient experience

Moderator – Christina Ullrich, MD, MPH Assistant Professor in Pediatrics, Harvard Medical School Pediatric Hematology/Oncology and Palliative Care, Boston Children's Hospital/ Dana Farber Cancer Institute

# Disclosures

The following faculty and planning committee staff have no financial disclosures:

Name	Institution
Eric Roeland, MD	University California San Diego Moores Cancer Center
Areej El-Jawahri MD	Blood and Marrow Transplant Program Massachusetts General Hospital
Effie Petersdorf, MD	University of Washington, Fred Hutchinson Cancer Research Center
Thomas LeBlanc, MD	Duke Cancer Institute
Ellen Denzen, MS	National Marrow Donor Program/Be The Match
Christa Meyer, MS	National Marrow Donor Program/Be The Match

# Disclosures

The following faculty and planning committee staff have the following financial disclosures:

Name	Institution	Disclosure
Christina Ullrich, MD, MPH	Boston Children's Hospital / Dana- Farber Cancer Institute Harvard Medical School	Schulman IRB

# Learning objectives

At the conclusion of this session, attendees will be able to:

- Synthesize the evidence-base for palliative and supportive care in HCT
- Discuss HCT physicians' perceptions of and attitudes on the gaps in delivering palliative and supportive care
- Recognize the collaborative role of the multi-disciplinary care team in meeting palliative and supportive care needs of HCT patients
- Discover barriers to palliative and supportive care and the patient/caregiver experience



# Integration of Palliative Care into the Care of Hematopoietic Stem Cell Transplantation Patients

Eric Roeland, MD, FAAHPM Oncology & Palliative Care UC San Diego Moores Cancer Center

THE MATCH' COUNCIL MEETING: Sharing Our Passion For Life

## Outline

- Discuss the difference between palliative care and hospice care
- Briefly review the data regarding palliative care integration into solid tumor cancer care
- Review palliative care needs in hematologic malignancies
- Review SHIELD palliative care study

## **Palliative Care Compared to Hospice**


Hospice

Palliative Care Supportive Care

THE MATCH' COUNCIL MEETING: Sharing Our Passion For Life

MARROW DONOR PROGRAM

## **Palliative Care: Old & New Approaches**



MARROW DONOR PROGRAM

## **Integrative Palliative Care Studies in Oncology**

- 7 randomized controlled trials
  - Bakitas et al, 2009 ENABLE II study
  - Temel et al, 2010
  - Zimmerman et al, 2014
  - Bakitas et al, 2015 ENABLE III study
  - Grudzen et al, 2016
  - Temel et al, 2016
  - El-Jawahri et al, 2016
- Reference slides attached to end of presentation as a resource
- No study to date has shown harm


## **Professional Society Recommendations**

- American Society of Clinical Oncology
  - "any patient with metastatic cancer  $\pm$  high symptom burden"
- American College of Surgeons, Commission on Cancer
  - "required to offer palliative care either on site or by referral"
- National Comprehensive Cancer Network
  - "develop processes for integrating palliative care into cancer care, both as part of usual oncology care and for patients with specialty palliative care needs"
- Oncology Nursing Society
  - "All patients with cancer benefit from palliative care
  - "Palliative care should begin at time of diagnosis"

# What about hematopoietic stem cell transplantation (HSCT)?




#### **High Symptom Burden in Hematologic Malignancies**





NATIONAL MARROW DONOR PROGRAM

#### **Unmet End-of-Life Needs in Hematologic Malignancies**



NATIONAL MARROW DONOR PROGRAM

**COUNCIL MEETING:** Sharing Our Passion For Life


Hui, Cancer 2014

#### Hematologic Malignancies: Unmet Palliative Care Needs


- Patients with hematologic malignancies have substantial unmet palliative care needs throughout their illness trajectory
  - Psychological trauma of unexpected diagnosis
  - Intensive therapies leading to significant symptom burden
  - Unmet end-of-life care needs
  - Survivors struggle with long-term complications

## **SHIELD: Study Design**


160 patients with hematologic malignancies within 72 hour of admission for HCT (and their willing family caregivers)







### **SHIELD: Palliative Care Intervention**




**COUNCIL MEETING:** Sharing Our Passion For Life

NATIONAL MARROW DONOR PROGRAM

BE THE MATCH

El-Jawahri JAMA 316(20) 2016

#### **SHIELD: Palliative Care Intervention**



NATIONAL MARROW DONOR PROGRAM

#### **SHIELD: Patient Week-2 Outcomes**

Week-2 Outcomes	Adjusted Mean Difference	95% CI	P- Value
FACT – BMT	7.73	1.27 to 14.19	0.019
FACT – Fatigue	3.88	0.21 to 7.54	0.038
ESAS – Symptom Burden	-6.26	-11.46 to -1.05	0.019
HADS – Depression symptoms	-1.74	-3.01 to -0.47	0.008
HADS – Anxiety symptoms	-2.26	-3.22 to -1.29	<0.001
PHQ-9 – Depression	-1.28	-2.82 to 0.27	0.104

**COUNCIL MEETING:** Sharing Our Passion For Life



El-Jawahri JAMA 316(20) 2016 19

## **SHIELD: Patient 3-Month Outcomes**

3-Month Outcomes	Adjusted Mean Difference	95% CI	P- Value
FACT – BMT	5.34	0.04 to 10.65	0.048
FACT – Fatigue	2.00	-1.08 to 5.09	0.202
ESAS – Symptom Burden	-2.44	-6.29 to 1.41	0.212
HADS – Depression	-1.70	-2.75 to -0.65	0.002
symptoms			
HADS – Anxiety symptoms	-0.76	-1.73 to 0.23	0.130
PHQ-9 – Depression	-2.12	-3.42 to -0.81	0.002
PCL – PTSD Symptoms	-4.35	-7.12 to -1.58	0.002



**COUNCIL MEETING:** Sharing Our Passion For Life


El-Jawahri JAMA 316(20) 2016 20

## **SHIELD: Patient 6-Month Outcomes**

6 Month Outcomes	Adjusted Mean Difference	95% CI	P- Value
FACT – BMT	2.72	-2.96 to 8.39	0.346
FACT – Fatigue	0.10	-3.38 to 3.58	.957
HADS – Depression	-1.21	-2.26 to -0.16	0.024
HADS – Anxiety symptoms	-0.61	-1.69 to 0.47	0.267
PHQ-9 – Depression	-1.63	-3.08 to -0.19	0.027
PCL – PTSD Symptoms	-4.02	-7.18 to -0.86	0.013



#### **SHIELD: Psychological Distress at 6-Months**



NATIONAL MARROW DONOR PROGRAM

## **SHIELD: Caregiver Outcomes**

2-week Caregiver Outcomes	Adjusted mean difference	95% CI	P-value
HADS-Depression	-1.65	-3.01 to -0.29	0.018
HADS-Anxiety	-0.14	-1.56 to 1.27	0.84
QOL	3.38	-1.59 to 8.35	0.180

- Improvement in two domains of QOL
  - Coping: adjusted mean difference = 1.01, P = 0.009
  - Administrative/finances: adjusted mean difference = 0.67, P = 0.029

MARROW DONOR PROGRAM

### **SHIELD: Palliative care in HSCT Summary**

- Inpatient palliative care improved QOL, symptom burden, depression, and anxiety symptoms in patients with hematologic malignancies undergoing HCT.
- Caregivers also experienced improvement in certain domains of QOL and lower depression symptoms.
- A relatively brief inpatient palliative care intervention led to remarkable sustained improvements in patient depression and post-traumatic stress 3 & 6 months post-HCT.
- First study showing the benefits of palliative care for patients with hematologic malignancies undergoing curative therapy.

## Where Do We Go from Here?

- Further need for proof-of-principal trials in novel populations of patients with hematologic malignancies
- Developing palliative care models that are tailored to the need of patients and their families
- Understanding mechanism of the benefits of palliative care
- Who benefits the most from early palliative care integration?
- Developing less resource-intensive models/ telemedicine
- Developing primary palliative care interventions

# **Palliative Care & Oncology Studies**

Study	Population	Intervention	Control	QOL /mood	Healthcare utilization	Survival	Caregiver outcomes
Bakitas 2009	Advanced stage solid tumor with prognosis 1 year	n=161 Telephone-based, manualized, nursing-led multicomponent psychoeducational intervention	n=161 Usual care	1			
Temel 2010	Patients with newly diagnosed metastatic lung cancer	n=77 Early integrated PC with monthly outpatient PC clinic visits	n=74 Usual care	1	Ļ	1	
Zimmerman 2014	Patients with stage III/IV lung, GI, GU, gynecologic cancer with prognosis 6-24 months	n=228 PC consultation and at least monthly follow-up in PC clinic	n=233 Usual care	1	Ļ		



# Palliative Care & Oncology Studies...

Study	Population	Intervention	Control	QOL/ mood	Healthcare utilization	Survival	Caregiver outcomes
Bakitas 2015	Patients with advanced stage solid tumor or hematologic malignancy (n=10, 4.8%) with prognosis 6-24 months	n=104 Early initiation of PC (within 30-60 days of diagnosis) Involving outpatient in- person PC consult, 6 weekly telephone coaching session by advanced practice nurse using manual	n=103 Delayed initiation of PC (3 months afterdiag nosis)			One- year survival: yes Overall survival: no	1
Grudzen 2016	Patients with advanced stage solid tumor in the emergency department	n=69 PC consultation by inpatient team, refer to outpatient PC clinic if appropriate	n=67 Usual care	1	Ļ	Ļ	

# Palliative Care & Oncology Studies...

Study	Population	Intervention	Control	QOL/ mood	Healthcare utilization	Survival	Caregiver outcomes
Temel 2016	Patients with newly diagnosed incurable lung or noncolorectal GI cancer	n=175 Early integrated PC with monthly outpatient PC clinic visits	n=175 Usual care	Lung cancer : ↑ GI cancer : 			pending
El-Jawahri 2016	Caregivers of patients with new diagnosis of incurable lung or non-colorectal GI cancer	n=137 PC visit for patient within 4 weeks of enrollment and at least monthly until death. Caregivers encouraged, but not required to attend.	n= 138 Usual care	1			1

## Integrative Palliative Care Studies in Oncology Citations for Reference

1. Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. *JAMA*. 2009;302(7):741-749.

2. El-Jawahri A, Podgurski LM, Eichler AF, et al. Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. *Journal of Clinical Oncology.* 2010;28(2):305-310.

3. Zimmermann C, Swami N, Krzyzanowska M, et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. *The Lancet.* 2014;383(9930):1721-1730.

4. Bakitas MA, Tosteson TD, Li Z, et al. Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial. *Journal of Clinical Oncology.* 2015;33(13):1438-1445.

5. El-Jawahri A LT, VanDusen H, et al. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplnation: a randomized clinical trial. *Jama.* 2016.

6. Ferrell BR, Temel JS, Temin S, et al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. *Journal of Clinical Oncology.* 2016:JCO. 2016.2070. 1474.

7. Grudzen CR, Richardson LD, Johnson PN, et al. Emergency Department–Initiated Palliative Care in Advanced Cancer: A Randomized Clinical Trial. *JAMA oncology.* 2016.





#### Transplant Physicians' Perspectives on Palliative Care

Areej El-Jawahri MD Blood and Marrow Transplant Program Massachusetts General Hospital MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER

#### Outline

- Barriers to Palliative Care Integration
- Transplant Physicians' Perspectives on Palliative Care: A National Survey
- Overcoming Barriers with Successful Models of Integration
- Insights from Palliative Care and Transplant Physicians on a Model of Early Palliative Care Integration
- Where do we go from here?





#### **Barriers to Palliative Care Integration**

- Substantial unmet palliative and supportive care needs for patients undergoing HCT
  - -Prior to transplant
  - -During the acute hospitalization for HCT
  - -Survivorship and chronic GVHD
  - -End of life
- Barriers to palliative care utilization
  - -Illness specific barriers
  - –System based barriers
  - -Cultural barriers





#### **Illness Specific Barriers**

- Patients with Hematologic Conditions are just different:
  - Prognostic uncertainty
  - Absence of clear transition between curative phase and palliative phase of treatment
  - Rapid and unpredictable trajectory of decline at the EOL
  - Complications at the EOL are also different:
    - •Need for blood product support
    - Infectious complications
    - Bleeding complications

El-Jawahri, Curr. Hematol 2016





#### **System-Based Barriers**

- Lack of access to high-quality palliative care services
- Lack of Infrastructure for outpatient palliative care
- Difficulty managing GVHD complications in this population
- EOL care delivery models  $\rightarrow$  not developed for this population
- Lack of understanding of what death looks like for a hememalignancy patients
- Lack of preparation for family


El-Jawahri, Curr. Hematol 2016 El-Jawahri, JOP 2017





#### **Cultural Barriers**

- Misperceptions equating palliative care with just EOL care.
- Lack of exposure to palliative care mistrust.
- Palliative care services have not been exposed enough to this population.







#### **Transplant Physicians Survey**

- Current access and collaboration with palliative care
- Physicians' sense of ownership over addressing palliative care issues
- Attitudes & perceptions of palliative care
- Perceived barriers to palliative care utilization
- Perceived unmet palliative care needs in this population





## **Transplant Physicians Survey**

Participant Characteristics N(%)	N = 277
Male gender	179 (65%)
Hispanic	22 (8%)
Race	
White	194 (70%)
Asian	51 (21%)
African American	7 (3%)
Other	19 (7%)
US region of practice	
Midwest	89 (32%)
South Atlantic	53 (19%)
South Central	50 (18%)
Northeast	33 (12%)
Mountain	27 (10%)
Pacific	25 (9%)
Years of clinical practice since completing training	
< 10 years	101 (36%)
10-20 years	80 (29%)
> 10 years	96 (35%)






### **Transplant Physicians Survey**

Participant Characteristics N(%)	N = 277
What patient age group do you provide care	
Adults only	179 (65%)
Pediatrics only	77 (28%)
Adults and Pediatrics	21 (8%)
For what patient population do you provide care	
Both non-transplant and transplant patients	159 (57%)
Transplant patients only	118 (43%)
Number of adult transplants performed at your center	
< 50 total transplants per year	13 (6%)
50-200 transplants per year	98 (42%)
> 200 transplants per year	123 (52%)
Don't know	1 (0%)
Training in palliative care	
Attended CME courses & educational lectures	128 (46%)
No training	102 (37%)
Rotation during residency or fellowship	81 (29%)
6 months or more of formal training	4 (1%)





## **Collaboration & Quality of PC Services**








#### **Ownership over PC Issues**

#### Transplant Physicians' Ownership over Palliative Care Issues



Transplant physician shouldTransplant physician should be an Transplant physician should be ancoordinate the care of patients at expert in management of physical<br/>all stages of their diseaseexpert in management of<br/>psychological symptoms of<br/>hematologicincluding EOLdiseaseshematologic diseases


Agree Neutral Disagree





#### **Attitudes about PC**

#### **Transplant Physicians' Attitudes towards Palliative Care**








#### **Attitudes about PC**

# Physicians' perceptions: "When patients hear the term palliative care"








### **Attitudes about PC**

#### If a palliative care referral is suggested for a patient, they might:








#### **Barriers to PC Utilization**

#### **Regarding "Palliative Care"**








### **Barriers to PC Utilization**

#### Perceived Barriers to Palliative Care Utilization








#### **Perceived Unmet Palliative Care Needs**

#### **Perceived Unmet Palliative Care Needs**



Agree Neutral Disagree





# **Summary of Findings**

- Access to high-quality palliative care services continue to be limited, especially in the outpatient setting
- Transplant physicians can trust & collaborate with PC clinicians, but feel like PC clinicians need more exposure to HCT
- Transplant physicians have major concerns regarding patients' reaction to palliative care
- Patient, provider, and cultural barriers to PC identified
- There are immense unmet PC needs in this population





## **Integration Strategies**

- Rigorous studies targeting the needs of patients undergoing HCT.
- Identify the role of early palliative care for patients with certain hematologic conditions.
- Build trust & break down misperceptions about palliative care.
- Focus first on how palliative care can help HCT survivors to break down misperceptions about EOL care
- Increase access to inpatient and outpatient palliative care services → innovative delivery models







- Collaborative engagement: BMT clinicians, nursing, palliative care, and patients & families
- Focus on the science and rationale in cultivating trust
- Start by breaking misperceptions about palliative care
  - –First palliative care intervention  $\rightarrow$  focused on symptoms management
  - -Building trust



ORe



## **Early PC: Insights from Oncology**

- Palliative care has more tools in their toolbox for symptom management.
- Palliative care clinicians have expertise in helping patients cope/accept/adapt to their illness.
- Patients do not have a negative perception of palliative care.
- Palliative care is not just about end of life care.





## **Early PC: Insights from Palliative Care**

- Palliative care must learn the unique needs of a particular population of patients with cancer.
  - –Understand chemo regimen
  - -Side effect profiles
  - -Illness trajectory
- Deeper understanding of prognostic uncertainty in patients with hematologic malignancies & those receiving curative therapy.
- Importance of establishing trusting relationship with oncology.





## Where Do We Go from here?

- Patient survey of attitudes and perceptions of palliative care
- More research & clinical care models integrating palliative care for HCT patients
  - -Collaborative care models
  - -Consultative models
  - -Embedded care models
- Developing palliative care models that are tailored to the need of patients and their families.
- Developing less resource-intensive models/ telemedicine.
- Developing primary palliative care interventions.





#### **COUNCIL MEETING** Sharing Our Passion For Life

# **Panel Discussion**

#### Moderator:

Christina Ullrich, MD, MPH: Boston Children's Hospital / Dana-Farber Cancer Institute Harvard Medical School

#### Panel:

MARROW DONOR PROGRAM

Eric Roeland, MD: University California San Diego Moores Cancer Center Areej El-Jawahri MD: Blood and Marrow Transplant Program Massachusetts General Hospital

# **Evaluation Reminder**

Please complete the Council Meeting 2017 evaluation in order to receive continuing education credits and to provide suggestions for future topics.

# We appreciate your feedback!